Kodiak Sciences (NASDAQ:KOD) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Kodiak Sciences (NASDAQ:KOD) posted its quarterly earnings data on Thursday. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.06, Zacks reports.

Kodiak Sciences Stock Up 1.7 %

Shares of NASDAQ KOD opened at $3.06 on Friday. The stock’s fifty day simple moving average is $4.93 and its 200 day simple moving average is $5.40. The stock has a market capitalization of $161.03 million, a price-to-earnings ratio of -0.84 and a beta of 2.26. Kodiak Sciences has a 52-week low of $2.19 and a 52-week high of $11.60.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Monday, December 9th.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.